[.
]Action/Kinetics:
Contains solubilized crystalline estrone stabilized with piperazine.
Uses:
PO: Moderate to severe vasomotor symptoms associated with menopause. Vulval and vaginal atrophy. Primary ovarian failure, female castration, female hypogonadism. Prevention of osteoporosis.
Vaginal: Atrophic vaginitis and kraurosis vulvae associated with menopause.
Contraindications:
Use during pregnancy.
How Supplied:
Vaginal cream: 1.5 mg/g; Tablet: 0.75 mg, 1.5 mg, 3 mg
Dosage
•Tablets
Moderate to severe vasomotor symptoms; atrophic vaginitis or kraurosis vulvae due to menopause.
0.75-6 mg/day for short-term therapy (give cyclically). May also be used continuously. The lowest dose that will control symptoms should be selected. Attempt to discontinue or taper the dose at 3- to 6-month intervals.
Hypogonadism, primary ovarian failure, castration.
1.5-9 mg/day (calculated as 0.625 to 5 mg estrone sulfate) for first 3 weeks; then, rest period of 8-10 days. A PO progestin can be given during the third week if withdrawal bleeding does not occur.
Prevention of osteoporosis.
0.625 mg/day for 25 days of a 31-day cycle per month. Mainstays of therapy include calcium; exercise and nutrition may be important adjuncts.
•Vaginal Cream
2-4 g (containing 3-6 mg estropipate) daily (depending on severity of condition) for 3 weeks followed by a 1-week rest period. Attempt to taper the dose or discontinue the medication at 3- to 6-month intervals.
Discuss prescriptions and health topics in the new 